Practical aspects of antithrombotic therapy in patients with atrial fibrillation and coronary artery disease
https://doi.org/10.15829/1560-4071-2021-4653
Abstract
Atrial fibrillation (AF) is the most common cardiac arrhythmia, which is associated with an increased risk of cardiovascular death. The latter is partly due to the common combination with coronary artery disease (CAD). If indicated, patients with AF need continuous direct oral anticoagulant therapy to prevent thromboembolic events. In addition, patients with CAD who require urgent or elective percutaneous coronary intervention require dual antiplatelet therapy. Therefore, physicians often face a dilemma when choosing the most appropriate antithrombotic therapy regimen for AF patients undergoing percutaneous coronary intervention. Integrating two medication approaches to treat a single patient with a combination of AF and CAD is challenging and must strike a balance between high efficacy and safety. This article provides an overview of studies on this issue.
About the Authors
Zh. D. Kobalava
Peoples’ Friendship University of Russia
Russian Federation
Russian Federation
Moscow
A. A. Shavarov
Peoples’ Friendship University of Russia
Russian Federation
Russian Federation
Moscow
References
1. Montalescot G, Sechtem U, Achenbach S, et al. ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949- 3003. doi:10.1093/eurheartj/eht296.
2. Kirchhof P, Benussi S, Kotecha D, et al. ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;27:2893-962. doi:10.1093/eurheartj/ehw210.
3. National Institutes of Health NH, Lung, and Blood Institute. Morbidity & Mortality: 2012 Chart Book on Cardiovascular, Lung, and Blood Diseases. Bethesda, MD: National Heart, Lung, and Blood Institute. 2012. Available at: https://www.nhlbi.nih.gov/files/docs/research/2012_ChartBook_508.pdf.
4. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990- 2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;9963:117-71. doi:10.1016/S0140-6736(14)61682-2.
5. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2020:ehaa612. doi:10.1093/eurheartj/ehaa612.
6. Arakelyan MG, Bockeria LA, Vasilieva EYu, et al. Clinical guidelines for Atrial fibrillation and atrial flutter. Russian Journal of Cardiology. 2021;26(7):4594. (In Russ.) doi:10.15829/1560-4071-2021-4594.
7. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019;74:104-32. doi:10.1016/j.jacc.2019.01.011.
8. Neumann FJ, Sousa-Uva M, Ahlsson A, et al., ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40:87-165. doi:10.1093/eurheartj/ehy394.
9. Connolly S, Ezekowitz M, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Eng J Med. 2009;361:1139-51. doi:10.1056/NEJMoa0905561.
10. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-92. doi:10.1056/NEJMoa1107039.
11. Patel MR, Mahaffey KW, Garg J, et al.; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-91. doi:10.1056/NEJMoa1009638.
12. Van Gelder IC, Groenveld HF, Crijns HJ, et al. Race II Investigators. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010;362(15):1439-41. doi:10.1056/NEJMoa1001337.
13. AFFIRM Investigators, Baseline characteristics of patients with atrial fibrillation: the AFFIRM study. Am Heart J. 2002;143(6):991-1001. doi:10.1067/mhj.2002.122875.
14. Hohnloser SH, Crijns HJ, van Eickels M, et al, ATHENA Investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360:668-78. doi:10.1056/NEJMoa0803778.
15. Kralev S, Schneider K, Lang S, et al. Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography. PLoS One. 2011;6(9):e24964.
16. Lip GYH, Beevers DG. ABC of atrial fibrillation: history, epidemiology and importance of atrial fibrillation. BMJ. 1995;311(7016):1361-3. doi:10.1136/bmj.311.7016.1361.
17. Nous FMA, Budde RPJ, van Dijkman ED, et al. Prognostic value of subclinical coronary artery disease in atrial fibrillation patients identified by coronary computed tomography angiography. Am J Cardiol. 2020;126:16-22. doi:10.1016/j.amjcard.2020.03.050.
18. Loukianov MM, Andrenko EY, Martsevich SY, et al. Patients with atrial fibrillation in clinical practice: comorbidity, drug treatment and outcomes (Data from RECVASA Registries). Rational Pharmacotherapy in Cardiology. 2020;16(6):888-98. (In Russ.) doi:10.20996/1819-6446-2020-12-01.
19. Zhirov IV, Safronova NV, Osmolovskaya YF, Тereshchenko SN. Prognostic value of atrial fibrillation in patients with heart failure and different left ventricular ejection fraction: results of the multicenter RIFCHF register. Russian Journal of Cardiology. 2021;26(1):4200. (In Russ.) doi:10.15829/1560-4071-2021-4200.
20. AFFIRM Investigators, Clinical factors that influence response to treatment strategies in atrial fibrillation: The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study. Am Heart J. 2005;149:645-9. doi:10.1016/j.ahj.2004.09.038.
21. Suttorp MJ, Kingma JH, Koomen EM, et al. Recurrence of paroxysmal atrial fibrillation or flutter after successful cardioversion in patients with normal left ventricular function. Am J Cardiol. 1993;71:710-13. doi:10.1016/0002-9149(93)91015-a.
22. Flaker GC, Belew K, Beckman K, et al. Asymptomatic atrial fibrillation: demographic features and prognostic information from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J. 2005;149:657-63. doi:10.1016/j.ahj.2004.06.032.
23. Corley SD, Epstein AE, DiMarco JP, et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation. 2004;109:1509-13. doi:10.1161/01.CIR.0000121736.16643.11.
24. Schmitt J, Duray G, Gersh BJ, Hohnloser SH. Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. Eur Heart J. 2009;30(9):1038-145. doi:10.1093/eurheartj/ehn579.
25. Jabre P, Jouven X, Adnet F, et al. Atrial fibrillation and death after myocardial infarction: a community study. Circulation. 2011;17(19):2094-100. doi:10.1161/CIRCULATIONAHA.110.990192.
26. Alasady M, Abhayaratna WP, Leong DP, et al. Coronary artery disease affecting the atrial branches is an independent determinant of atrial fibrillation after myocardial infarction. Heart Rhythm. 2011;8(7):955-60. doi:10.1016/j.hrthm.2011.02.016.
27. Kundu A, O’Day K, Shaikh AY, et al. Relation of atrial fibrillation in acute myocardial infarction to in-hospital complications and early hospital readmission. Am J Cardiol. 2016;15(8):1213-8. doi:10.1016/j.amjcard.2016.01.012.
28. Pedersen OD, Abildstrom SZ, Ottesen MM, et al. Increased risk of sudden and non-sudden cardiovascular death in patients with atrial fibrillation/flutter following acute myocardial infarction. Eur Heart J. 2006;27:290-5. doi:10.1093/eurheartj/ehi629.
29. Lehto M, Snapinn S, Dickstein K, et al. Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: the OPTIMAAL experience. Eur Heart J. 2005;26(4):350-6. doi:10.1093/eurheartj/ehi064.
30. Aranki SF, Shaw DP, Adams DH, et al. Predictors of atrial fibrillation after coronary artery surgery: current trends and impact on hospital resources. Circulation. 1996;94(3):390-7. doi:10.1161/01.cir.94.3.390.
31. Mathew JP, Parks R, Savino JS, et al. Atrial fibrillation following coronary artery bypass graft surgery: predictors, outcomes, and resource utilization. MultiCenter Study of Perioperative Ischemia Research Group. JAMA. 1996;276(4):300-6.
32. Aronow WS, Ahn C, Mercando AD, Epstein S. Correlation of atrial fibrillation, paroxysmal supraventricular tachycardia, and sinus rhythm with incidences of new coronary events in 1,359 patients, mean age 81 years, with heart disease. Am J Cardiol. 1995;75:182-4. doi:10.1016/s0002-9149(00)80074-0.
33. Goto S, Bhatt DL, Rother J, et al. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J. 2008;156:855-63. doi:10.1016/j.ahj.2008.06.029.
34. Taguchi I, Iimuro S, Iwata H, et al. High-dose versus low-dose pitavastatin in japanese patients with stable coronary artery disease (REAL-CAD). Circulation. 2018;137:1997- 2009. doi:10.1161/CIRCULATIONAHA.117.032615.
35. Pilgrim T, Kalesan B, Zanchin T, et al. Impact of atrial fibrillation on clinical outcomes among patients with coronary artery disease undergoing revascularization with drugeluting stents. EuroIntervention. 2013;22(9):1061-71. doi:10.4244/EIJV8I9A163.
36. Otterstad JE, Kirwan B-A, Lubsen J, et al. Incidence and outcome of atrial fibrillation in stable symptomatic coronary disease. Scand Cardiovasc J. 2006;40(3):152-9. doi:10.1080/14017430600746268.
37. Hohnloser SH, Oldgren J, Yang S, et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial. Circulation. 2012;125:669-76. doi:10.1161/CIRCULATIONAHA.111.055970.
38. Dans AL, Connolly SJ, Wallentin L, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial. Circulation. 2013;127:634-40. doi:10.1161/CIRCULATIONAHA.112.115386.
39. Mahaffey KW, Stevens SR, White HD, et al. Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. Eur Heart J. 2014;35:233-41. doi:10.1093/eurheartj/eht428.
40. Bahit MC, Lopes RD, Wojdyla DM, et al. Apixaban in patients with atrial fibrillation and prior coronary artery disease: Insights from the ARISTOTLE trial. Int J Cardiol. 2013;170:215-20. doi:10.1016/j.ijcard.2013.10.062.
41. Fauchier L, Samson A, Chaize G, et al. Cause of death in patients with atrial fibrillation admitted to French hospitals in 2012: a nationwide database study. Open Heart. 2015;2(1):e000290. doi:10.1136/openhrt-2015-000290.
42. Pokorney SD, Piccini JP, Stevens SR, et al. Cause of death and predictors of all-cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: data from ROCKET AF. J Am Heart Assoc. 2016;5(3):e002197. doi:10.1161/JAHA.115.002197.
43. Centers for Disease Control and Prevention. Underlying Cause of Death, 1999-2018. CDC WONDER Online Database. Atlanta, GA: Centers for Disease Control and Prevention; 2018. Accessed March 12, 2020.
44. Connolly S, Pogue J, Hart R, et al. ACTIVE Writing Group of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367:1903-12. doi:10.1016/S0140-6736(06)68845-4.
45. Sorensen R, Hansen ML, Abildstrom SZ, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet. 2009;374:1967-74. doi:10.1016/S0140-6736(09)61751-7.
46. Toyoda K, Yasaka M, Iwade K, et al. Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease: a prospective, multicenter, observational study. Stroke. 2008;39:1740-5. doi:10.1161/STROKEAHA.107.504993.
47. Uchida Y, Mori F, Ogawa H, et al. Impact of anticoagulant therapy with dual antiplatelet therapy on prognosis after treatment with drug-eluting coronary stents. J Cardiol. 2010;55:362-9. doi:10.1016/j.jjcc.2009.12.014.
48. Dabi A, Koutrouvelis AP. Reversal strategies for intracranial hemorrhage related to direct oral anticoagulant medications. Crit Care Res Pract. 2018;2018:4907164. doi:10.1155/2018/4907164.
49. Spyropoulos AC, Douketis JD. How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood. 2012;120:2954-62. doi:10.1182/blood-2012-06-415943.
50. Boehringer Ingelheim, Inc. Praxbind prescribing information. Food and Drug Administration. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761025lbl.pdf.
51. Portola Pharmaceuticals. U.S. FDA approves Portola Pharmaceuticals Andexxa®, the first and only antidote for the reversal of factor Xa inhibitors [media release]. 3 May 2018.
52. Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibril - lation undergoing PCI. N Engl J Med. 2016;375:2423-34. doi:10.1056/NEJMoa1611594.
53. Cannon CP, Bhatt DL, Oldgren J, et al.; RE-DUAL PCI Steering Committee and Investigators. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017;377:1513-24. doi:10.1056/NEJMoa1708454.
54. Lopes RD, Heizer G, Aronson R, et al.; AUGUSTUS Investigators. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med. 2019;380(16):1509-24. doi:10.1056/NEJMoa1817083.
55. Steffel J, Verhamme P, Potpara TS, et al.; ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330-93. doi:10.1093/eurheartj/ehy136.
Review
For citations:
Kobalava Zh.D., Shavarov A.A. Practical aspects of antithrombotic therapy in patients with atrial fibrillation and coronary artery disease. Russian Journal of Cardiology. 2021;26(9):4653. (In Russ.) https://doi.org/10.15829/1560-4071-2021-4653
Views:
946
Email this article 